Wheaton Precious Metals Corp (WPM) Stock Price Today
Key Stats
- $51.34BMarket Cap
- -Volume
- Basic MaterialsSector
- $165.7252W High
- $91.0252W Low
- -Typical Hold Time
- $49.19BEnterprise Value
- 0.69%Div Yield
- -Trading Activity
Track Wheaton Precious Metals Corp (WPM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Wheaton Precious Metals Corp has traded between a low of $91.02 and a high of $165.72, highlighting its annual price range. Buy and sell Wheaton Precious Metals Corp shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Most Recent News
Subsea7 wins $50-$150M contract for offshore pipeline work in Brunei with Brunei Shell Petroleum.
Subsea7 has been awarded a sizeable contract by Brunei Shell Petroleum to handle the subsea installation for a Pipeline Replacement Project offshore Brunei. The contract involves engineering, procurement, construction, and installation (EPCI) of subs...

Global SaaS market to hit $600-650B by 2030 as AI and product-led growth reshape marketing.
The global SaaS market, valued at $310-330 billion in 2025, is projected to nearly double to $600-650 billion by 2030, driven by cloud adoption, AI integration, and product-led growth strategies. SaaS companies are shifting marketing investments towa...

Novo Nordisk's ZEUS trial shows no cardiovascular event reduction with ziltivekimab in high-risk patients.
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.